Vol 12, No 6 (2016)
Review paper
Published online: 2017-06-02
Is cetuximab in combination with irinotecan as a third-line treatment for advanced colorectal cancer scientifically justified?
DOI: 10.5603/OCP.2016.0016
Oncol Clin Pract 2016;12(6):205-208.
Abstract
Not available